JNJ-pan-AR, a meylated analogue of JNJ-63576253, is a novel pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. JNJ63576253, also known as TRC253, is a potent and orally active androgen receptor antagonist. TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus.